US20110092524A1 - Agent for Enhancing Corneal Epithelial Barrier Function - Google Patents

Agent for Enhancing Corneal Epithelial Barrier Function Download PDF

Info

Publication number
US20110092524A1
US20110092524A1 US12/866,625 US86662509A US2011092524A1 US 20110092524 A1 US20110092524 A1 US 20110092524A1 US 86662509 A US86662509 A US 86662509A US 2011092524 A1 US2011092524 A1 US 2011092524A1
Authority
US
United States
Prior art keywords
methyl
phenyl
ethoxy
methoxy
pparγ agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/866,625
Inventor
Shin-Ichiro Hirai
Atsushi Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Assigned to SANTEN PHARMACEUTICAL CO., LTD. reassignment SANTEN PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HIRAI, SHIN-ICHIRO, YOSHIDA, ATSUSHI
Publication of US20110092524A1 publication Critical patent/US20110092524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention relates to an agent for enhancing a corneal epithelial barrier function including a PPAR ⁇ agonist as active ingredient.
  • a cornea is a transparent avascular tissue with a diameter of approximately 1 cm and a thickness of approximately 1 mm, is formed of corneal epithelium and corneal stroma, and has been known to have a significant effect on visual function.
  • a barrier formation between the ambient of the cornea and the corneal stroma As one of the important functions of the corneal epithelium, there can be mentioned a barrier formation between the ambient of the cornea and the corneal stroma.
  • a corneal epithelial bather function specifically is to regulate an invasion of substances present in lacrimal fluid, and pathogens, such as bacterium and fungus, from the corneal epithelium to the corneal stroma. It has been reported that the corneal epithelial barrier function is suppressed in a diabetes patient, and the corneal epithelial bather function becomes reduced with aging (Non-Patent Documents 1, 2, and 3). It is believed that, when the barrier function is decreased, various substances present on the surface of eye disorderly invade the cornea and then stimulate a sensory nerve of the cornea. This stimulation becomes a factor of an ocular discomfort.
  • Non-Patent Documents 4 and 5 it is also known that, when the corneal epithelial bather function collapse, an interaction between the corneal epithelium and the lacrimal fluid becomes disrupted, leading to lowering of functional visual acuity.
  • PPAR ⁇ is distributed in energy storing organs, such as white adipose tissue, and has an effect on differentiation and proliferation of adipocyte.
  • a PPAR ⁇ agonist there have been known compounds having a thiazolidinedione skeleton, such as 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), and 5-[p-[2-(methyl-2-pyridylamino
  • the PPAR ⁇ agonist improved insulin resistant diabetes, and was effective as therapeutic agent for disease attributed to insulin resistance, such as diabetes mellitus and hyperglycemia, as well as inflammatory disease, such as osteoarthritis and rheumatic arthritis (Patent Document 1).
  • the PPAR ⁇ agonist was effective as therapeutic agent for keratoconjunctive disorders, such as dry eye, corneal ulcer, keratitis, and conjunctivitis (Patent Documents 2, 3, and 4).
  • the present inventors performed enhancement tests of corneal epithelial barrier function using compounds functioning as PPAR ⁇ agonist. As a result, the present inventors found that these compounds remarkably enhanced the corneal epithelial barrier function, and completed the present invention.
  • the present invention is directed to:
  • an agent for enhancing the corneal epithelial barrier function that includes the PPAR ⁇ agonist as active ingredient (2) a preventive agent or therapeutic agent for ocular infection attributed to a decrease in the corneal epithelial barrier function that includes the PPAR ⁇ agonist as active ingredient, (3) an agent for ameliorating an ocular discomfort attributed to a decrease in the corneal epithelial barrier function that includes the PPAR ⁇ agonist as active ingredient, and (4) an agent for recovery of functional visual acuity that includes the PPAR ⁇ agonist as active ingredient.
  • the PPAR ⁇ agonist there is no specific limitation with respect to the PPAR ⁇ agonist as long as it is a compound functioning as PPAR ⁇ agonist (hereinbelow, simply referred to as “present compound”), and it may be a compound having a thiazolidinedione skeleton or a compound having no thiazolidinedione skeleton.
  • salt of the compound described above there is no limitation as long as it is pharmaceutically compatible, and examples include: a salt with inorganic acid, such as hydrochloric acid, nitric acid and sulfuric acid; a salt with organic acid, such as acetic acid, fumaric acid, maleic acid, succinic acid and tartaric acid; and a salt with alkali metal or alkali earth metal, such as sodium, potassium and calcium.
  • a preferable salt is a salt of hydrochloric acid.
  • a quaternary ammonium salt of the present compound is included in the salt in the present invention.
  • the isomer thereof is also included in the present invention. It should be noted that the present compound may be in a form of hydrate or solvate.
  • corneal epithelial barrier function refers to a function of regulating an invasion of substances present in lacrimal fluid, and an invasion of pathogens, such as bacterium and fungus, from the corneal epithelium to the corneal stroma.
  • the agent for enhancing the corneal epithelial barrier function of the present invention can enhance the corneal epithelial barrier function in a diabetes patient, a patient with a decrease in the conical epithelial barrier function due to aging, and a patient who underwent refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery.
  • corneal epithelial barrier function By enhancing the corneal epithelial barrier function, for example, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity.
  • the agent for enhancing the corneal epithelial barrier function of the present invention may be administered orally or parenterally.
  • types of administration include eye-drop, eye ointment, injectable, tablet, capsule, granule, and powder, and especially the eye-drop is preferred. These can be pharmaceutically formulated using common techniques.
  • a pharmaceutically formulation can be prepared using, if desired, isotonic agent, such as sodium chloride and concentrated glycerin; buffer agent, such as sodium phosphate and sodium acetate; surfactant, such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate, and polyoxyethylene hardened castor oil; stabilizing agent, such as sodium citrate and sodium edetate; and preservative agent, such as benzalkonium chloride and paraben.
  • isotonic agent such as sodium chloride and concentrated glycerin
  • buffer agent such as sodium phosphate and sodium acetate
  • surfactant such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate, and polyoxyethylene hardened castor oil
  • stabilizing agent such as sodium citrate and sodium edetate
  • preservative agent such as benzalkonium chloride and paraben.
  • the eye ointment In the case of the eye ointment, it can be prepared using common ointment base, such as white petrolatum and liquid paraffin.
  • the oral agent such as tablet, capsule, granule, and powder, if desired, there may be added: expander, such as lactose, crystalline cellulose, starch and vegetable oil; lubricant, such as magnesium stearate and talc; binder, such as hydroxylpropyl cellulose and polyvinylpyrrolidone; disintegrant, such as carboxy methylcellulose calcium and hydroxypropyl methylcellulose of low substitution; coating agent, such as hydroxypropyl methylcellulose, macrogol, and silicon resin; and film-forming agent, such as gelatin film.
  • expander such as lactose, crystalline cellulose, starch and vegetable oil
  • lubricant such as magnesium stearate and talc
  • binder such as hydroxylpropyl cellulose and polyvinylpyrrolidone
  • the dosage can be appropriately selected depending on symptoms, age, dosage form and the like, but it is preferred that, in the case of the eye-drop, a drop with 0.0001-1% (w/v), preferably 0.001-1% (w/v) is placed in the eye once or several times per day.
  • a drop with 0.0001-1% (w/v), preferably 0.001-1% (w/v) is placed in the eye once or several times per day.
  • the oral agent in general, 0.1-5,000 mg, preferably 1-1,000 mg thereof is administered once or several times per day.
  • the enhancement test of corneal epithelial barrier function elucidated that the compound of the present invention functioning as PPAR ⁇ agonist exhibited an excellent enhancing effect on the barrier function. Accordingly, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity.
  • the compound of the present invention can enhance the corneal epithelial barrier function in a diabetes patient, a patient with a decrease in the corneal epithelial bather function due to aging, and a patient with refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery.
  • PRK photorefractive keratectomy
  • LASIK laser in situ keratomileusis
  • the PPAR ⁇ agonist was evaluated with respect to the enhancing effect on the barrier function of a corneal epithelial cell.
  • a corneal epithelial cell an SV40-immortalized human corneal epithelial cell line was used, utilizing a membrane electrical resistance as an index of the barrier function.
  • the membrane electrical resistance increases, while the bather function is reduced, the membrane electrical resistance decreases.
  • HCE-T SV40-immortalized human corneal epithelial cells
  • the culture medium was removed after 9 hours, 2 days, 3 days and 4 days, and replaced with a culture medium containing one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), and 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), as PPAR ⁇ agonist with a thiazolidinedi
  • an electrical resistance of an epithelial cell layer was measured using a membrane electrical resistance measurement system (World Precision Instruments).
  • a well containing the base medium alone with no corneal epithelial cell seeded was measured as a blank, and the value was subtracted from the electrical resistance of the epithelial cell layer.
  • the resultant value was multiplied by an area of the cell culture (0.33 cm 2 ), to thereby obtain an electrical resistance ( ⁇ cm 2 ) per unit area.
  • the membrane electrical resistance (average of four experiments) of each sample is shown in Table 1.
  • HCE-T SV40-immortalized human corneal epithelial cells
  • the culture medium was removed after 9 hours, 2 days, 3 days and 4 days, and replaced with a culture medium containing the PPAR ⁇ agonist and the PPAR ⁇ antagonist to thereby obtain samples.
  • a culture medium containing the PPAR ⁇ agonist and the PPAR ⁇ antagonist As the PPAR ⁇ agonist, rivoglitazone [0.1 ⁇ M] was used, and as the PPAR ⁇ antagonist, 2-chloro-5-nitrobenzanilide (GW-9662) [0.03 ⁇ M, 0.1 ⁇ M] was used.
  • the concentrations mentioned above were attained by dissolving each sample in DMSO and diluting 1,000-fold with the culture medium.
  • a culture containing DMSO alone was used as a base culture medium.
  • an electrical resistance of an epithelial cell layer was measured using a membrane electrical resistance measurement system (World Precision Instruments).
  • a well containing the base medium alone with no corneal epithelial cell seeded was measured as a blank, and the value was subtracted from the electrical resistance of the epithelial cell layer.
  • the resultant value was multiplied by an area of the cell culture (0.33 cm 2 ), to thereby obtaining an electrical resistance ( ⁇ cm 2 ) per unit area.
  • the membrane electrical resistance (average of four experiments) of each sample is shown in Table 2.
  • the barrier function enhanced by rivoglitazone was concentration-dependently reduced by GW-9662 (PPAR ⁇ antagonist), and completely antagonized at 0.1 ⁇ M.
  • PPAR ⁇ agonist rivoglitazone
  • GW-9662 PPAR ⁇ antagonist
  • eye-drop with various concentrations, such as 0.001% (w/v), 0.01% (w/v), 0.03% (w/v), 0.1% (w/v), 0.3% (w/v), 1.0% (w/v), and 3.0% (w/v), can be prepared.
  • Disodium hydrogenphosphate 100 mg
  • eye-drop with various concentrations such as 0.1% (w/v), 0.3% (w/v), 0.5% (w/v), 1.5% (w/v), and 3% (w/v), can be prepared.
  • Rivoglitazone 0.3 g
  • Liquid paraffin 10.0 g
  • eye ointment with various concentrations, such as 1% (w/w) and 3% (w/w), can be prepared.
  • Liquid paraffin 10.0 g
  • eye ointment with various concentrations, such as 1% (w/w) and 3% (w/w), can be prepared.
  • the compound functioning as the PPAR ⁇ agonist remarkably enhances the corneal epithelial barrier function.
  • enhancing the corneal epithelial barrier function for example, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity.

Abstract

The invention relates to a pharmacological action of a compound which functions as a PPARγ agonist on the barrier function of the corneal epithelium. A PPARγ agonist such as rivoglitazone, DRF-2593, GW-544 or BMS-298585 exhibits an excellent effect of enhancing the corneal epithelial barrier function in a test for enhancement of corneal epithelial barrier function, and therefore is useful as a preventive agent or a therapeutic agent for ocular infection or ocular unidentified complaint caused by a decrease in the corneal epithelial barrier function. Further, the PPARγ agonist can enhance the corneal epithelial barrier function of diabetic patients, patients with decreased corneal epithelial barrier function due to aging and patients who underwent refractive surgery such as PRK (photorefractive keratectomy) or LASIK (laser in situ keratomileusis) or cataract surgery.

Description

    TECHNICAL FIELD
  • The present invention relates to an agent for enhancing a corneal epithelial barrier function including a PPARγ agonist as active ingredient.
    • BACKGROUND ART
  • A cornea is a transparent avascular tissue with a diameter of approximately 1 cm and a thickness of approximately 1 mm, is formed of corneal epithelium and corneal stroma, and has been known to have a significant effect on visual function.
  • As one of the important functions of the corneal epithelium, there can be mentioned a barrier formation between the ambient of the cornea and the corneal stroma. Such a corneal epithelial bather function specifically is to regulate an invasion of substances present in lacrimal fluid, and pathogens, such as bacterium and fungus, from the corneal epithelium to the corneal stroma. It has been reported that the corneal epithelial barrier function is suppressed in a diabetes patient, and the corneal epithelial bather function becomes reduced with aging (Non-Patent Documents 1, 2, and 3). It is believed that, when the barrier function is decreased, various substances present on the surface of eye disorderly invade the cornea and then stimulate a sensory nerve of the cornea. This stimulation becomes a factor of an ocular discomfort.
  • It has been also reported that, in the case of refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery, the corneal epithelial bather function is reduced after the operation, and various pathogens invade the eye, which may cause infectious diseases (Non-Patent Documents 4 and 5). In addition, it is also known that, when the corneal epithelial bather function collapse, an interaction between the corneal epithelium and the lacrimal fluid becomes disrupted, leading to lowering of functional visual acuity.
  • It has been known that PPARγ is distributed in energy storing organs, such as white adipose tissue, and has an effect on differentiation and proliferation of adipocyte. As a PPARγ agonist, there have been known compounds having a thiazolidinedione skeleton, such as 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), and 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), and a compound having no thiazolidinedione skeleton, such as N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), and N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585).
  • It has been reported that the PPARγ agonist improved insulin resistant diabetes, and was effective as therapeutic agent for disease attributed to insulin resistance, such as diabetes mellitus and hyperglycemia, as well as inflammatory disease, such as osteoarthritis and rheumatic arthritis (Patent Document 1). In addition, it has been also reported that the PPARγ agonist was effective as therapeutic agent for keratoconjunctive disorders, such as dry eye, corneal ulcer, keratitis, and conjunctivitis (Patent Documents 2, 3, and 4).
  • However, no report has been made with respect to the study of the above-described compound in terms of enhancing effect on the corneal epithelial barrier function. To examine a pharmacological effect of the compound functioning as PPARγ agonist on the corneal epithelial barrier function is very intriguing task.
    • Patent Document 1: Japanese Patent Publication No. 2976885
    • Patent Document 2: Japanese Patent Application Publication No. 2005-145961
    • Patent Document 3: Japanese Patent Application Publication No. 2005-162735
    • Patent Document 4: Japanese Patent Application Publication No. 2005-350451
    • Non-Patent Document 1: The Cornea. Scientific Foundations and Clinical Practice. Third Edition. (1994) 25-46
    • Non-Patent Document 2: Cornea 1993; 12(6): 493-499
    • Non-Patent Document 3: Cornea 2004; 23(1): 35-37
    • Non-Patent Document 4: Journal of Refractive Surgery 1999; 15 (2 suppl): S221-S224
    • Non-Patent Document 5: International Ophthalmology 1995-1996; 19(4): 225-233
    DISCLOSURE OF THE INVENTION
  • In order to examine the involvement of the PPARγ agonist in the corneal epithelial barrier function, the present inventors performed enhancement tests of corneal epithelial barrier function using compounds functioning as PPARγ agonist. As a result, the present inventors found that these compounds remarkably enhanced the corneal epithelial barrier function, and completed the present invention.
  • Accordingly, the present invention is directed to:
  • (1) an agent for enhancing the corneal epithelial barrier function that includes the PPARγ agonist as active ingredient,
    (2) a preventive agent or therapeutic agent for ocular infection attributed to a decrease in the corneal epithelial barrier function that includes the PPARγ agonist as active ingredient,
    (3) an agent for ameliorating an ocular discomfort attributed to a decrease in the corneal epithelial barrier function that includes the PPARγ agonist as active ingredient, and
    (4) an agent for recovery of functional visual acuity that includes the PPARγ agonist as active ingredient.
  • In the present invention, there is no specific limitation with respect to the PPARγ agonist as long as it is a compound functioning as PPARγ agonist (hereinbelow, simply referred to as “present compound”), and it may be a compound having a thiazolidinedione skeleton or a compound having no thiazolidinedione skeleton. Examples of the compound having a thiazolidinedione skeleton includes, 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), and 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone) and examples of the compound having no thiazolidinedione skeleton includes N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), E-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloximino]-4-phenyl butyric acid (TAK-559), Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloximino]-2-(4-phenoxyphenyl)acetic acid (TAK-664), 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY-293111), 2(S)-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propionic acid (LY-519818), (−)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid 2-(acetylamino)ethyl ester (MBX-102), and (+2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid.
  • With respect to the salt of the compound described above, there is no limitation as long as it is pharmaceutically compatible, and examples include: a salt with inorganic acid, such as hydrochloric acid, nitric acid and sulfuric acid; a salt with organic acid, such as acetic acid, fumaric acid, maleic acid, succinic acid and tartaric acid; and a salt with alkali metal or alkali earth metal, such as sodium, potassium and calcium. A preferable salt is a salt of hydrochloric acid. In addition, a quaternary ammonium salt of the present compound is included in the salt in the present invention. Further, when a geometric isomer or an optical isomer of the present compound is present, the isomer thereof is also included in the present invention. It should be noted that the present compound may be in a form of hydrate or solvate.
  • In the present invention, the expression “corneal epithelial barrier function” refers to a function of regulating an invasion of substances present in lacrimal fluid, and an invasion of pathogens, such as bacterium and fungus, from the corneal epithelium to the corneal stroma. The agent for enhancing the corneal epithelial barrier function of the present invention can enhance the corneal epithelial barrier function in a diabetes patient, a patient with a decrease in the conical epithelial barrier function due to aging, and a patient who underwent refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery.
  • By enhancing the corneal epithelial barrier function, for example, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity.
  • The agent for enhancing the corneal epithelial barrier function of the present invention may be administered orally or parenterally. Examples of types of administration include eye-drop, eye ointment, injectable, tablet, capsule, granule, and powder, and especially the eye-drop is preferred. These can be pharmaceutically formulated using common techniques. For example, in the case of eye-drop, a pharmaceutically formulation can be prepared using, if desired, isotonic agent, such as sodium chloride and concentrated glycerin; buffer agent, such as sodium phosphate and sodium acetate; surfactant, such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate, and polyoxyethylene hardened castor oil; stabilizing agent, such as sodium citrate and sodium edetate; and preservative agent, such as benzalkonium chloride and paraben. There is no limitation with respect to pH as long as it is compatible with ophthalmologic preparation, but a range of 4-8 is preferable.
  • In the case of the eye ointment, it can be prepared using common ointment base, such as white petrolatum and liquid paraffin. In the case of the oral agent, such as tablet, capsule, granule, and powder, if desired, there may be added: expander, such as lactose, crystalline cellulose, starch and vegetable oil; lubricant, such as magnesium stearate and talc; binder, such as hydroxylpropyl cellulose and polyvinylpyrrolidone; disintegrant, such as carboxy methylcellulose calcium and hydroxypropyl methylcellulose of low substitution; coating agent, such as hydroxypropyl methylcellulose, macrogol, and silicon resin; and film-forming agent, such as gelatin film.
  • The dosage can be appropriately selected depending on symptoms, age, dosage form and the like, but it is preferred that, in the case of the eye-drop, a drop with 0.0001-1% (w/v), preferably 0.001-1% (w/v) is placed in the eye once or several times per day. In the case of the oral agent, in general, 0.1-5,000 mg, preferably 1-1,000 mg thereof is administered once or several times per day.
  • As will be described later, the enhancement test of corneal epithelial barrier function elucidated that the compound of the present invention functioning as PPARγ agonist exhibited an excellent enhancing effect on the barrier function. Accordingly, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity. In addition, the compound of the present invention can enhance the corneal epithelial barrier function in a diabetes patient, a patient with a decrease in the corneal epithelial bather function due to aging, and a patient with refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Results of the pharmacological tests and embodiments of pharmaceutical preparations will be described below. These are illustrated for the purpose of helping better understanding of the present invention, and it should not be construed that these limit the scope of the present invention.
    • [Pharmacological Test 1] Enhancing Effect of PPARγ Agonist on Barrier Function
  • The PPARγ agonist was evaluated with respect to the enhancing effect on the barrier function of a corneal epithelial cell. For the corneal epithelial cell, an SV40-immortalized human corneal epithelial cell line was used, utilizing a membrane electrical resistance as an index of the barrier function. When the bather function of the corneal epithelial cell is enhanced, the membrane electrical resistance increases, while the bather function is reduced, the membrane electrical resistance decreases.
    • (Experimental Methodology)
  • From RIKEN BioResource Center, SV40-immortalized human corneal epithelial cells (HCE-T) were obtained. On a culture insert of 24-well Transwell Clear (Corning incorporated) were seeded 6.4×104 cells of HCE-T, and incubated at 37° C. in 5% CO2. As the culture medium, a DMEM/Ham's F12 (Nacalai Tesque, Inc.) containing 15% fetal bovine serum (ICN) and 40 μg/mL of gentamicin (Gibco) was used. The culture medium was removed after 9 hours, 2 days, 3 days and 4 days, and replaced with a culture medium containing one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), and 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), as PPARγ agonist with a thiazolidinedione skeleton, each in an amount of 10 μM, or a culture medium containing one of N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyrosine (GW-544), and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), as PPARγ agonist with a non-thiazolidinedione skeleton, each in an amount of 10 μM, to thereby obtain samples. The concentration mentioned above was attained by dissolving each sample in DMSO and diluting 1,000-fold with the culture medium. In addition, a culture medium containing DMSO alone was used as a base culture medium.
  • Five days after the seeding, an electrical resistance of an epithelial cell layer was measured using a membrane electrical resistance measurement system (World Precision Instruments). A well containing the base medium alone with no corneal epithelial cell seeded was measured as a blank, and the value was subtracted from the electrical resistance of the epithelial cell layer. The resultant value was multiplied by an area of the cell culture (0.33 cm2), to thereby obtain an electrical resistance (Ω·cm2) per unit area.
    • (Result)
  • The membrane electrical resistance (average of four experiments) of each sample is shown in Table 1.
  • TABLE 1
    Membrane electrical resistance
    Sample [10 μM] (Ω · cm2)
    Rivoglitazone 615.9
    DRF-2593 485.8
    Pioglitazone 350.3
    Rosiglitazone 343.2
    GW-544 435.3
    BMS-298585 375.1
    Base culture 296.0
    • (Considerations)
  • As is apparent from Table 1, all of the PPARγ agonists used in the present pharmacological test showed higher electrical resistance than that of the base culture medium. In other words, it was shown that the PPARγ agonist, regardless of the presence of the thiazolidinedione skeleton, enhanced the barrier function of the corneal epithelial cell. Especially, rivoglitazone, DRF-2593, BMS-298585, and GW-544 showed an excellent barrier function enhancing effect, and still especially rivoglitazone exhibited an extremely strong barrier function enhancing effect.
    • [Pharmacological Test 2] Influence of PPARγ Antagonist on Barrier Function Enhancing Effect of PPARγ Agonist
  • An influence of the PPARγ antagonist was evaluated with respect to the barrier function enhancing effect of the PPARγ agonist, and it was examined whether or not the enhancing effect on the barrier function is based on the activity of the PPARγ agonist.
    • (Experimental Methodology)
  • From RIKEN BioResource Center, SV40-immortalized human corneal epithelial cells (HCE-T) were obtained. On a culture insert of 24-well Transwell Clear (Corning Incorporated) were seeded 6.4×104 cells of HCE-T, and incubated at 37° C. in 5% CO2. As the culture medium, a DMEM/Ham's F12 (Nacalai Tesque, Inc.) containing 15% fetal bovine serum (ICN) and 40 μg/mL of gentamicin (Gibco) was used. The culture medium was removed after 9 hours, 2 days, 3 days and 4 days, and replaced with a culture medium containing the PPARγ agonist and the PPARγ antagonist to thereby obtain samples. As the PPARγ agonist, rivoglitazone [0.1 μM] was used, and as the PPARγ antagonist, 2-chloro-5-nitrobenzanilide (GW-9662) [0.03 μM, 0.1 μM] was used. The concentrations mentioned above were attained by dissolving each sample in DMSO and diluting 1,000-fold with the culture medium. In addition, a culture containing DMSO alone was used as a base culture medium.
  • Five days after the seeding, an electrical resistance of an epithelial cell layer was measured using a membrane electrical resistance measurement system (World Precision Instruments). A well containing the base medium alone with no corneal epithelial cell seeded was measured as a blank, and the value was subtracted from the electrical resistance of the epithelial cell layer. The resultant value was multiplied by an area of the cell culture (0.33 cm2), to thereby obtaining an electrical resistance (Ω·cm2) per unit area.
    • (Result)
  • The membrane electrical resistance (average of four experiments) of each sample is shown in Table 2.
  • TABLE 2
    Membrane electrical resistance
    Sample (Ω · cm2)
    Rivoglitazone (0.1 μM) 538.8
    Rivoglitazone (0.1 μM) and 473.5
    GW-9662 (0.03 μM)
    Rivoglitazone (0.1 μM) and 429.3
    GW-9662 (0.1 μM)
    Base culture 434.1
    • (Considerations)
  • As is apparent from Table 2, the barrier function enhanced by rivoglitazone (PPARγ agonist) was concentration-dependently reduced by GW-9662 (PPARγ antagonist), and completely antagonized at 0.1 μM. In other words, it was shown that the enhancing effect of rivoglitazone on the corneal epithelial cell bather function is PPARγ-dependent. The results above elucidate that, when the compound has the PPARγ agonist activity, the compound can enhance the barrier function of the corneal epithelial cell.
    • EXAMPLES OF PHARMACEUTICAL FORMULATION
  • Representative pharmaceutical formulations using the PPARγ agonist will be described below.
    • Formulation Example 1 In 100 ml
  • Rivoglitazone: 10 mg
  • Sodium chloride: 900 mg
  • Sterile purified water: appropriate amount
  • By altering the amount of rivoglitazone, eye-drop with various concentrations, such as 0.001% (w/v), 0.01% (w/v), 0.03% (w/v), 0.1% (w/v), 0.3% (w/v), 1.0% (w/v), and 3.0% (w/v), can be prepared.
    • Formulation Example 2 In 100 ml
  • DRF-2593: 100 mg
  • Sodium chloride: 800 mg
  • Disodium hydrogenphosphate: 100 mg
  • Sodium dihydrogenphosphate: appropriate amount
  • Sterile purified water: appropriate amount
  • By altering the amount of DRF-2593, eye-drop with various concentrations, such as 0.1% (w/v), 0.3% (w/v), 0.5% (w/v), 1.5% (w/v), and 3% (w/v), can be prepared.
    • Formulation Example 3 In 100 g
  • Rivoglitazone: 0.3 g
  • Liquid paraffin: 10.0 g
  • White petrolatum: appropriate amount
  • By altering the amount of rivoglitazone, eye ointment with various concentrations, such as 1% (w/w) and 3% (w/w), can be prepared.
    • Formulation Example 4 In 100 g
  • GW-544: 0.3 g
  • Liquid paraffin: 10.0 g
  • White petrolatum: appropriate amount
  • By altering the amount of GW-544, eye ointment with various concentrations, such as 1% (w/w) and 3% (w/w), can be prepared.
    • INDUSTRIAL APPLICABILITY
  • The compound functioning as the PPARγ agonist remarkably enhances the corneal epithelial barrier function. By enhancing the corneal epithelial barrier function, for example, it becomes possible to prevent or treat ocular infection attributed to a decrease in the corneal epithelial barrier function, to ameliorate the ocular discomfort attributed to a decrease in the corneal epithelial barrier function, and to repair the disrupted interaction between the corneal epithelium and the lacrimal fluid to prevent lowering of functional visual acuity.

Claims (24)

1. An agent for enhancing a corneal epithelial barrier function comprising a PPARγ agonist as active ingredient.
2. The agent for enhancing a corneal epithelial bather function according to claim 1, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
3. A preventive or therapeutic agent for ocular infection attributed to a decrease in a corneal epithelial bather function comprising a PPARγ agonist as active ingredient.
4. The preventive or therapeutic agent for ocular infection attributed to a decrease in a corneal epithelial barrier function according to claim 3, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
5. An agent for ameliorating ocular discomfort attributed to a decrease in a corneal epithelial barrier function comprising a PPARγ agonist as active ingredient.
6. The ameliorating agent for ocular discomfort attributed to a decrease in a corneal epithelial barrier function according to claim 5, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyrosine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
7. An agent for recovery of functional visual acuity comprising a PPARγ agonist as active ingredient.
8. The agent for recovery of functional visual acuity according to claim 7, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
9. A therapeutic method for a disorder attributed to a decrease in a corneal epithelial barrier function comprising a step of administering a pharmacologically effective amount of a PPARγ agonist to a patient.
10. The therapeutic method for a disorder attributed to a decrease in a corneal epithelial barrier function according to claim 9, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyrosine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
11. A preventive or therapeutic method for ocular infection attributed to a decrease in a corneal epithelial bather function comprising a step of administering a pharmacologically effective amount of a PPARγ agonist to a patient.
12. The preventive or therapeutic method for ocular infection attributed to a decrease in a corneal epithelial bather function according to claim 11, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
13. A therapeutic method for ocular discomfort attributed to a decrease in a corneal epithelial barrier function comprising a step of administering a pharmacologically effective amount of a PPARγ agonist to a patient.
14. The therapeutic method for ocular discomfort attributed to a decrease in a corneal epithelial barrier function according to claim 13, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
15. A therapeutic method for recovering functional visual acuity comprising a step of administering a pharmacologically effective amount of a PPARγ agonist to a patient.
16. The therapeutic method for recovering functional visual acuity according to claim 15, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
17. A use of a PPARγ agonist for producing an agent for enhancing a corneal epithelial barrier function.
18. The use of a PPARγ agonist for producing an agent for enhancing a corneal epithelial barrier function according to claim 17, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-yl methoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyrosine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
19. A use of a PPARγ agonist for producing a preventive or therapeutic agent for ocular infection attributed to a decrease in a corneal epithelial barrier function.
20. The use of a PPARγ agonist for producing a preventive or therapeutic agent for ocular infection attributed to a decrease in a corneal epithelial barrier function according to claim 19, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
21. A use of a PPARγ agonist for producing an ameliorating agent for ocular discomfort attributed to a decrease in a corneal epithelial barrier function.
22. The use of a PPARγ agonist for producing an ameliorating agent for ocular discomfort attributed to a decrease in a corneal epithelial barrier function according to claim 21, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
23. A use of a PPARγ agonist for producing an agent for recovery of functional visual acuity.
24. The use of a PPARγ agonist for producing the agent for recovery of functional visual acuity according to claim 23, wherein the PPARγ agonist is at least one of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (rivoglitazone), 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione (DRF-2593), 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione (rosiglitazone), N-[1-methyl-3-oxo-3-phenyl-1(Z)-propenyl]-O-[2-(5-methyl-2-phenyloxazol-4-yl)ethyl]-L-tyro sine (GW-544), N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine (BMS-298585), and a salt thereof.
US12/866,625 2008-02-25 2009-02-25 Agent for Enhancing Corneal Epithelial Barrier Function Abandoned US20110092524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-043325 2008-02-25
JP2008043325 2008-02-25
PCT/JP2009/053398 WO2009107652A1 (en) 2008-02-25 2009-02-25 Agent for enhancing corneal epithelial barrier function

Publications (1)

Publication Number Publication Date
US20110092524A1 true US20110092524A1 (en) 2011-04-21

Family

ID=41016040

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/866,625 Abandoned US20110092524A1 (en) 2008-02-25 2009-02-25 Agent for Enhancing Corneal Epithelial Barrier Function

Country Status (8)

Country Link
US (1) US20110092524A1 (en)
EP (1) EP2253325A4 (en)
JP (1) JP2009227668A (en)
KR (1) KR20100137417A (en)
CN (1) CN101959531A (en)
CA (1) CA2716418A1 (en)
RU (1) RU2484848C2 (en)
WO (1) WO2009107652A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127443A1 (en) * 2002-08-10 2004-07-01 Pershadsingh Harrihar A. Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20070054943A1 (en) * 2004-05-11 2007-03-08 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
US20070060628A1 (en) * 2003-10-24 2007-03-15 Masatsugu Nakamura Therapeutic agent for keratoconjunctival disorder
US20070093514A1 (en) * 2003-10-29 2007-04-26 Masatsugu Nakamura Therapeutic agent for keratoconjunctival disorder
US20090306111A1 (en) * 2005-11-28 2009-12-10 Yoshikuni Nakamura Pharmaceutical Comprising PPAR Agonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005162735A (en) * 2003-10-29 2005-06-23 Santen Pharmaceut Co Ltd Remedy for keratoconjunctive disorder
WO2005099759A1 (en) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. Medicine for prevention and/or treatment of arteriosclerosis
JP2005350451A (en) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd Agent for treating keratoconjunctival trouble

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127443A1 (en) * 2002-08-10 2004-07-01 Pershadsingh Harrihar A. Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20070054949A1 (en) * 2002-08-10 2007-03-08 Pershadsingh Harrihar A Compositions comprising novel PPAR ligands and anti-hyperlipemic agents
US20070185070A1 (en) * 2002-08-10 2007-08-09 Bethesda Pharmaceuticals, Inc. Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20070203213A1 (en) * 2002-08-10 2007-08-30 Pershadsingh Harrihar A Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20080242712A1 (en) * 2002-08-10 2008-10-02 Bethesda Pharmaceuticals Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
US20110046188A1 (en) * 2002-08-10 2011-02-24 Bethesda Pharmaceuticals, Inc. Compositions comprising novel ppar ligands and anti-hyperlipemic agents
US20070060628A1 (en) * 2003-10-24 2007-03-15 Masatsugu Nakamura Therapeutic agent for keratoconjunctival disorder
US7358255B2 (en) * 2003-10-24 2008-04-15 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
US20070093514A1 (en) * 2003-10-29 2007-04-26 Masatsugu Nakamura Therapeutic agent for keratoconjunctival disorder
US20070054943A1 (en) * 2004-05-11 2007-03-08 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
US20090306111A1 (en) * 2005-11-28 2009-12-10 Yoshikuni Nakamura Pharmaceutical Comprising PPAR Agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lu et al., Corneal Epithelial wound healing, July 2001. *

Also Published As

Publication number Publication date
CN101959531A (en) 2011-01-26
RU2484848C2 (en) 2013-06-20
EP2253325A1 (en) 2010-11-24
CA2716418A1 (en) 2009-09-03
RU2010139400A (en) 2012-04-10
WO2009107652A1 (en) 2009-09-03
JP2009227668A (en) 2009-10-08
KR20100137417A (en) 2010-12-30
EP2253325A4 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
JP4217832B2 (en) Treatment for keratoconjunctival disorders
US11951103B2 (en) Pharmaceutical composition
RU2704813C2 (en) Prolonged release pharmaceutical composition
CN105555364A (en) The local treatment of inflammatory ophthalmic diseases
CN111683682A (en) Drug for preventing or treating ophthalmic diseases accompanied by intraocular angiogenesis and/or intraocular vascular hyperpermeability
US20110092524A1 (en) Agent for Enhancing Corneal Epithelial Barrier Function
US9321745B2 (en) Inhibition of neovascularization by inhibition of prostanoid IP receptors
US7348329B2 (en) Therapeutic agent for keratoconjunctival disorder
JP4922588B2 (en) Treatment for keratoconjunctival disorder
US20070054943A1 (en) Therapeutic agent for keratoconjunctival disorder
JP2006104199A (en) Agent for treatment of keratoconjunctive disorder
JP2020075918A (en) Ophthalmic composition for promoting corneal epithelium wound cure
KR20070053283A (en) Therapeutic agent for keratoconjunctiva disorder
JP2005350451A (en) Agent for treating keratoconjunctival trouble
JP2005008570A (en) Agent for treating corneal disease
RU2423127C2 (en) Therapeutic medication against corneal-conjunctival disturbance
JP2005162735A (en) Remedy for keratoconjunctive disorder
US9295665B2 (en) Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
US20210106569A1 (en) Omidenepag combination
WO2016199871A1 (en) Therapeutic agent for neurotrophic keratopathy

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANTEN PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HIRAI, SHIN-ICHIRO;YOSHIDA, ATSUSHI;REEL/FRAME:025433/0044

Effective date: 20100819

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION